Brand: ProteoGenix

Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade

Isotype:: IgG1

€200.00

+ 200 loyalty points

Size Size

100ug €200.00
1MG €800.00

First Name This field is required. Last Name This field is required. Email This field is required. Company This field is required. Country This field is required. State This field is required.

In Stock
Free shipping in EU on orders > €500
Wide range of unique reagents
Fast worldwide delivery

SDS-PAGE for Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb binds to CD158a / KIR2DL1, C-His, recombinant protein in INdirect ELISA Assay

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade

Product name	Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
Source	CAS 1000676-41-4
Species	Homo sapiens
Purity	>85%
Buffer	PBS buffer PH7.5
Delivery condition	Blue ice (+4°C)
Delivery Time	3-5 days if in stock; 3-5 weeks if production needed
Storage condition	store at -80°C
Brand	ProteoGenix
Applications	ELISA,WB
Aliases /Synonyms	Lirilumab,BMS-986015,IPH2102,KIRD2 subgroup,anti-KIRD2 subgroup
Reference	PX-TA1297
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype	Human IgG1
Clonality	Monoclonal Antibody

Product name	Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade
Source	CAS 1000676-41-4
Species	Homo sapiens
Expression system	Mammalian cells
Purity	>85%
Buffer	PBS buffer PH7.5
Delivery condition	Blue ice (+4°C)
Delivery Time	3-5 days if in stock; 3-5 weeks if production needed
Storage condition	store at -80°C
Brand	ProteoGenix
Applications	ELISA,WB,,,
Aliases /Synonyms	Lirilumab,BMS-986015,IPH2102,KIRD2 subgroup,anti-KIRD2 subgroup
Reference	PX-TA1297
Note	For research use only. Not suitable for clinical or therapeutic use.
Isotype	Human IgG1
Clonality	Monoclonal Antibody

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

Lirilumab has been investigated for the treatment of Leukemia, Cancer, Multiple Myeloma, Lymphocytic Leukemia, and Acute Myeloid Leukemia.

SDS-PAGE for Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb binds to CD158a / KIR2DL1, C-His, recombinant protein in INdirect ELISA Assay

Immobilized CD158a / KIR2DL1, C-His, recombinant protein (cat. No.PX-P5573) at 0.5µg/mL (100µL/well) can bind to Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb (cat. No.PX-TA1297) in indirect ELISA with Goat Anti-Human IgG secondary antibody coupled with HRP measured by OD450

Furkan Yigitbilek, Elif Ozdogan, Nitin Abrol, Walter D. Park, Michael J. Hansen, Surendra Dasari, Mark D. Stegall and Timucin Taner,Liver mesenchymal stem cells are superior inhibitors of NK cell functions through differences in their secretome compared to other mesenchymal stem cells,Front. Immunol., 21 September 2022, Sec. Alloimmunity and Transplantation, https://doi.org/10.3389/fimmu.2022.952262

There are no reviews yet.

Be the first to review “Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Your rating *

In which application did you use the antibody? *

Did it work in your application? * Yes No

Your review *

Name *

Email *

Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

SDS-PAGE for Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb binds to CD158a / KIR2DL1, C-His, recombinant protein in INdirect ELISA Assay

Related products

Lirilumab ELISA Kit

Recently viewed products

Can’t find what you need?

Cart (0 Items)

Lirilumab Biosimilar – Anti-KIRD2 subgroup mAb – Research Grade

Specifications Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade

Description

General information on Anti-KIRD2 subgroup[Homo sapiens] (Lirilumab) Monoclonal Antibody

Documents

QC & Validation

SDS-PAGE for Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb binds to CD158a / KIR2DL1, C-His, recombinant protein in INdirect ELISA Assay

Publications

Reviews

Related products

Lirilumab ELISA Kit

Recently viewed products

Can’t find what you need?

Cart (0 Items)

Lirilumab Biosimilar - Anti-KIRD2 subgroup mAb - Research Grade